Literature DB >> 3262725

In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography.

P Martiat1, A Ferrant, D Labar, M Cogneau, A Bol, C Michel, J L Michaux, G Sokal.   

Abstract

Carbon-11 thymidine (TdR) uptake using positron emission tomography (PET) has been measured in ten patients with non-Hodgkin's lymphoma (NHL). The rate of TdR uptake (mean +/- s.d.) was of 0.009 +/- 0.006 mumol.100 cc-1.min-1 in low-grade NHL. This rate was 0.063 +/- 0.049 mumol.100 cc-1.min-1 in intermediate-grade NHL and 0.159 mumol.100 cc-1.min-1 in a patient with high-grade NHL. Lymphoma radioactivity reached a plateau at 0.42 +/- 0.22%. 100 cc-1 of the injected dose from 10 min after injection. The highest 11C uptakes were observed in the kidneys and in the liver (3.30 +/- 1.30 and 2.10 +/- 0.05%. 100 cc-1 of the injected dose, respectively). The lymphoma-to-muscle ratio was of 11.8 +/- 1.7, whereas the lymphoma-to-intestine ratio was of 1.5 +/- 0.7. Accordingly, the measurement of [11C]TdR uptake in the abdomen may need other imaging methods for adequate interpretation. The results suggest that [11C]TdR uptake using PET might be a method for noninvasively measuring cell proliferation in vivo.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3262725

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  11 in total

Review 1.  Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors.

Authors:  D A Mankoff; F Dehdashti; A F Shields
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

2.  Carcinoma of the major salivary glands.

Authors:  M G Dilkes; P G Russell; T Jones
Journal:  Ann R Coll Surg Engl       Date:  1992-09       Impact factor: 1.891

3.  Synthesis of isotope labeled oligonucleotides and their use in an NMR study of a protein-DNA complex.

Authors:  E R Kellenbach; M L Remerowski; D Eib; R Boelens; G A van der Marel; H van den Elst; J H van Boom; R Kaptein
Journal:  Nucleic Acids Res       Date:  1992-02-25       Impact factor: 16.971

Review 4.  Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology.

Authors:  Anthony F Shields
Journal:  Mol Imaging Biol       Date:  2006 May-Jun       Impact factor: 3.488

5.  Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment.

Authors:  Nicolas Graf; Ken Herrmann; Jürgen den Hollander; Falko Fend; Tibor Schuster; Hans-Jürgen Wester; Reingard Senekowitsch-Schmidtke; Christian Meyer zum Büschenfelde; Christian Peschel; Markus Schwaiger; Tobias Dechow; Andreas K Buck
Journal:  Mol Imaging Biol       Date:  2008-08-14       Impact factor: 3.488

6.  In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography.

Authors:  D L Francis; A Freeman; D Visvikis; D C Costa; S K Luthra; M Novelli; I Taylor; P J Ell
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

7.  Clinical application of 18F-FUdR in glioma patients--PET study of nucleic acid metabolism.

Authors:  M Kameyama; K Ishiwata; Y Tsurumi; J Itoh; K Sato; R Katakura; T Yoshimoto; J Hatazawa; M Ito; T Ido
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

8.  Evaluation of 2'-deoxy-2'-[18F]fluoro-5-methyl-1-beta-L: -arabinofuranosyluracil ([18F]-L: -FMAU) as a PET imaging agent for cellular proliferation: comparison with [18F]-D: -FMAU and [18F]FLT.

Authors:  Ryuichi Nishii; Andrei Y Volgin; Osama Mawlawi; Uday Mukhopadhyay; Ashutosh Pal; William Bornmann; Juri G Gelovani; Mian M Alauddin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-12-04       Impact factor: 9.236

9.  Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT.

Authors:  Andreas K Buck; Clemens Kratochwil; Gerhard Glatting; Malik Juweid; Martin Bommer; Djurdja Tepsic; Andreas T J Vogg; Torsten Mattfeldt; Bernd Neumaier; Peter Möller; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05-31       Impact factor: 9.236

10.  Clinical value of PET/CT with carbon-11 4DST in the evaluation of malignant and benign lung tumors.

Authors:  Ryuichi Nishii; Tsuneo Saga; Hitomi Sudo; Takashi Togawa; Junpei Kuyama; Toshiaki Tani; Takamasa Maeda; Masato Kobayashi; Toshihiko Iizasa; Masato Shingyoji; Makiko Itami; Kazunori Kawamura; Hiroki Hashimoto; Kana Yamazaki; Kentaro Tamura; Tatsuya Higashi
Journal:  Ann Nucl Med       Date:  2021-01-02       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.